STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENVB
  4. [Form 4] Enveric Biosciences, Inc. Insider Trading Activity

Enveric Biosciences (ENVB) awards 25,000 RSUs to its CIO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan. Each unit will convert into one share of common stock as it vests, subject to continued employment.

One-fourth of the RSUs vest after one year, with an additional one-thirty-sixth vesting monthly until any remaining units vest on the fourth anniversary of grant. Following this award, Facchini holds 27,755 shares of common stock, adjusted for a prior 12-for-1 reverse stock split effective October 28, 2025.

Positive

  • None.

Negative

  • None.
Insider Facchini Peter J.
Role Chief Innovation Officer
Type Security Shares Price Value
Grant/Award Common Stock 25,000 $0.00 --
Holdings After Transaction: Common Stock — 27,755 shares (Direct, null)
Footnotes (1)
  1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
RSUs granted 25,000 units Restricted stock units granted to Chief Innovation Officer
Grant price per share $0.0000 per share Reported transaction price for RSU-related common stock
Shares after transaction 27,755 shares Common stock holdings following the RSU grant
Initial vesting portion One-fourth of RSUs Vests on the one-year anniversary of grant
Ongoing vesting rate One-thirty-sixth monthly Vests each month after first anniversary
Final vesting horizon Fourth anniversary Any remaining RSUs vest on this date
Reverse stock split ratio 12-to-1 Common stock reclassified October 28, 2025
restricted stock units financial
"Represents the restricted stock units (the "RSUs") granted to the reporting person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"For each vested restricted stock unit, the reporting person will be entitled to receive one share"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
2020 Long-Term Incentive Plan financial
"granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended"
vesting financial
"One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Reverse Stock Split financial
"the common stock of the Company began trading on a split-adjusted basis ... (the "Reverse Stock Split")"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Facchini Peter J.
(Last)(First)(Middle)
C/O ENVERIC BIOSCIENCES, INC.
245 FIRST STREET, RIVERVIEW II, 18TH FL
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Innovation Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026A25,000(1)A$027,755(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
2. On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
/s/ Peter J. Facchini06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Enveric Biosciences (ENVB) report for Peter J. Facchini?

Enveric Biosciences reported a grant of 25,000 restricted stock units to Chief Innovation Officer Peter J. Facchini. These units are part of his equity compensation and will convert into common shares as they vest over time, subject to continued employment.

How do the 25,000 RSUs granted by Enveric Biosciences (ENVB) vest?

The 25,000 RSUs vest with one-fourth on the first anniversary of the grant date, then one-thirty-sixth each month thereafter. Any remaining units fully vest on the fourth anniversary, provided Facchini remains employed by Enveric Biosciences throughout the vesting period.

What will Peter J. Facchini receive for each vested RSU from Enveric Biosciences (ENVB)?

For each vested restricted stock unit, Peter J. Facchini will receive one share of Enveric Biosciences common stock. This structure directly links his potential equity ownership to the company’s share performance and his continued service during the vesting schedule.

How many Enveric Biosciences (ENVB) shares does Peter J. Facchini hold after this RSU grant?

After the RSU award, Peter J. Facchini is reported to hold 27,755 shares of Enveric Biosciences common stock. This figure reflects the company’s 12-for-1 reverse stock split that became effective on October 28, 2025, and is presented on a split-adjusted basis.

What reverse stock split did Enveric Biosciences (ENVB) implement and when?

Enveric Biosciences implemented a 12-for-1 reverse stock split effective October 28, 2025. Every 12 issued and outstanding common shares were reclassified into one share, and the share amounts reported in this insider filing have been adjusted to reflect that reverse split.